ATTO insider transaction filings
Attovia Therapeutics, Inc. — 14 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-13. Screen ATTO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-13 | 4 | WALSH COLIN — Director | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +23 more | EDGAR |
| 2026-08-13 | 4 | GOLDMAN SACHS GROUP INC GOLDMAN SACHS & CO. LLC GOLDMAN SACHS ASSET MANAGEMENT, L.P. Broad Street Principal Investments, L.L.C. WSLS OFFSHORE INVESTMENTS, SLP West Street Life Sciences I, L.P. WSLS EMP OFFSHORE INVESTMENTS, L.P. WSLS EMP ONSHORE INVESTMENTS, L.P. | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +23 more | EDGAR |
| 2026-08-10 | 4 | Deep Track Biotechnology Master Fund, Ltd. — 10% owner Deep Track Capital, LP — 10% owner KROIN DAVID — 10% owner | Conversion (C): 1,957,138 · Conversion (C): 18,181,818 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | venBio Global Strategic Fund IV, L.P. — 10% owner | Conversion (C): 2,311,870 · Conversion (C): 821,998 · Conversion (C): 665,147 · Purchase (P): 382,352 @ $17 · Conversion (C): 21,477,273 (derivative) @ $0 · Conversion (C): 7,636,362 (derivative) @ $0 · +1 more | EDGAR |
| 2026-08-07 | 4 | Redmile Group, LLC — 10% owner Green Jeremy — 10% owner Redmile Biopharma Investments III, L.P. — 10% owner | Conversion (C): 782,854 · Purchase (P): 200,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 782,854 (derivative) | EDGAR |
| 2026-08-07 | 4 | Sanofi — 10% owner | Conversion (C): 782,855 · Purchase (P): 300,000 @ $17 · Conversion (C): 782,855 (derivative) | EDGAR |
| 2026-08-06 | 4 | Frazier Life Sciences XI, L.P. — 10% owner FHMLS XI, L.P. — 10% owner FHMLS XI, L.L.C. — 10% owner | Conversion (C): 1,749,192 · Conversion (C): 1,590,175 · Conversion (C): 1,189,940 · Conversion (C): 961,322 · Purchase (P): 588,235 @ $17 · Conversion (C): 16,250,000 (derivative) @ $0 · +3 more | EDGAR |
| 2026-08-06 | 4 | Odrowaz Zaneta — Chief Business Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | GOLD MITCHELL — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | You Angie — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Attovia Therapeutics, Inc. — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Chen Hubert — Chief Medical Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Veiby Petter — Chief Scientific Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Attovia Therapeutics, Inc. — President and CEO, Director | Grant/award (A): 538,300 (derivative) @ $0 | EDGAR |
Recent 8-K events — Attovia Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ATTO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →